0241.HK | Ticker Profile

0241.HK

Alibaba Health Information Technology Limited

Healthcare · ·

$3.49

Data: 2026-05-28

✓ ETHICAL PASS

STRONG MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$7.5B

Total market value of the company

Trailing P/E

26.00

Premium valuation

Forward P/E

17.37

Based on estimated future earnings — lower means cheaper

Rev Growth

+7.6%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Alibaba Health Information Technology Limited

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products.

Country: Hong Kong Industry: Pharmaceutical Retailers

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

N/A

Core business does not involve prohibited activities

Debt Ratio

0.0%

Debt must be below 33% of total assets

Cash Ratio

0.0%

Interest-bearing cash below 33% of assets

Receivables

0.0%

Receivables below 49% of assets

Revenue Purity

0.0%

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$0.27

What our model estimates this business is worth per share

Margin of Safety

-1,199.8%

Trading above fair value — no margin of safety

Rating

Overall assessment combining ethics, valuation, and quality

Percentile

54.3th

Ranks in the top 46% of our 13,571 screened universe

Ethical Score

N/A

Valuation Score

61.0

Quality Score

43.8

Combined

41.4

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.317

Positive but modest risk-adjusted returns

Kelly Fraction

0.0048

Marginal edge — very small allocation suggested

Calmar Ratio

0.024

Drawdown risk outweighs the returns — higher risk profile

Annual Return

1.3%

Historical annualised return based on price data

Max Drawdown

-53.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.02

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

1.7%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go